Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of vitamin b2 in the preparation of medicines for preventing and treating fibrotic diseases

A technology for fibrotic diseases and vitamins, which is applied in the fields of diseases, drug combinations, blood diseases, etc., and can solve problems such as research reports on the prevention and treatment of vitamin B2 on fibrotic diseases.

Active Publication Date: 2022-01-18
SHENYANG PHARMA UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no research report on the effect of vitamin B2 on the prevention and treatment of fibrotic diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of vitamin b2 in the preparation of medicines for preventing and treating fibrotic diseases
  • Use of vitamin b2 in the preparation of medicines for preventing and treating fibrotic diseases
  • Use of vitamin b2 in the preparation of medicines for preventing and treating fibrotic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. Study on the anti-pulmonary fibrosis, liver fibrosis, kidney fibrosis and cardiac fibrosis effect of vitamin B2 based on the fibrosis marker protein α-SMA in vitro.

[0031] Lung epithelial cells A549 cells, hepatic stellate cells LX-2, renal tubular epithelial cells CD3 and primary cardiac fibroblasts were pre-treated with 300 μM vitamin B2 or vehicle, and then stimulated by 10 ng / mL TGF-β1 to Myofibroblasts were transformed to construct lung, liver, kidney and heart fibrosis models in vitro, and the fibrosis marker protein α-SMA was used to characterize the degree of fibrosis. Such as figure 1 As shown, after 10ng / ml TGF-β1 stimulated human lung epithelial cells A549, hepatic stellate cells LX-2, renal tubular epithelial cells CD3 and primary mouse cardiac fibroblasts for 48h, the fibrosis marker protein α-SMA Significantly up-regulated (P<0.01=demonstrates successful construction of classic lung, liver, kidney and heart fibrosis models). 300μM vitamin B2...

Embodiment 2

[0032]Example 2. Cell hardness as a marker of fibrosis To investigate the anti-pulmonary fibrosis, liver fibrosis, kidney fibrosis and heart fibrosis effects of vitamin B2 in vitro.

[0033] Our previous results demonstrated that cell stiffness can be used as a biomarker to characterize the degree of fibrosis. Lung epithelial cells A549 cells, hepatic stellate cells LX-2, renal tubular epithelial cells CD3 and primary cardiac fibroblasts were pre-treated with 300 μM vitamin B2 or vehicle, and then stimulated by 10 ng / mL TGF-β1 to Transformation of myofibroblasts to construct fibrosis models of lung, liver, kidney and heart in vitro. Atomic force microscopy was used to detect the changes in the stiffness of the above four cells after being stimulated by TGF-β1, and the cell stiffness (Young's modulus) was used as a marker to characterize degree of fibrosis. the result shows( figure 2 ), in the above models of pulmonary fibrosis, liver fibrosis, renal fibrosis and cardiac fib...

Embodiment 3

[0034] Example 3. Study on anti-fibrosis effect of vitamin B2 in vivo.

[0035] 1. Model preparation and administration:

[0036] Select adult male C57 mice with a body weight of 20-24g, respectively set up a blank control group (normal saline), a model group, and a test drug group (vitamin B2, 1.4g / kg, intragastric administration), 10 mice in each group animal. Bleomycin was administered at 3 mg / kg via tracheal perfusion to prepare a mouse model of pulmonary fibrosis; different test drugs were given on the 7th day after the bleomycin model was established, once a day for 21 consecutive days.

[0037] 2. Pathological tissue sampling:

[0038] On the 28th day after administration, the mouse was anesthetized by intraperitoneal injection of 0.1ml / 10g chloral hydrate, the chest cavity was opened, the left atrium was cut open, and pre-cooled normal saline was slowly injected into the heart from the right ventricle, and perfused through the pulmonary circulation until the lungs tu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine, and relates to the use of vitamin B2 in preparing medicines for treating and preventing fibrosis diseases. The vitamin B2 is vitamin B2 or its medicinal derivatives. The fibrotic diseases include pulmonary fibrosis, liver fibrosis, renal fibrosis, cardiac fibrosis, endometrial fibrosis, eye fibrosis, pancreatic fibrosis, spleen fibroproliferative disease, myelofibrosis disease or fibrosis induced disease. The vitamin B2 can form a pharmaceutical composition with one or more pharmaceutical carriers. Vitamin B2 or its pharmaceutical composition can be used alone or in combination with other drugs. And it has the advantages of significant curative effect, less toxic and side effects and safe use in treating fibrotic diseases.

Description

technical field [0001] The invention belongs to the field of new application of known medicines, and relates to the application of vitamin B2 in the preparation of medicines for preventing and treating different fibrosis diseases. Background technique [0002] Fibrosis is a pathological process in which the overexpression of cytokines induced by various etiologies leads to the activation and transformation of intrinsic function cells and mesenchymal cells, the accumulation of excess extracellular matrix, the destruction of tissue structure and the loss of function. Fibrosis can occur in many organs, including vital organs such as the lungs, liver, kidneys, and heart. The pathological process of fibrosis can be divided into ① induction phase (inflammatory response phase): cell damage caused by the primary pathogenic cause can induce the release of pro-fibrotic cytokines such as TGF-β1 and PDGF, resulting in the phenotype transformation of the tissue intrinsic cells and Accel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/525A61P11/00A61P1/16A61P13/12A61P9/00A61P15/00A61P27/02A61P1/18A61P1/14A61P7/06
CPCA61P1/14A61P1/16A61P1/18A61P7/06A61P9/00A61P11/00A61P13/12A61P15/00A61P27/02A61K31/525
Inventor 马恩龙王健李艳春刘禹彤
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com